Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report

As it prepares its latest regulatory submission in Alzheimer’s disease, Axsome has scored another clinical win, this time with a well-traveled DNRI that has met the primary endpoint in a Phase III study to treat ADHD.

Axsome Therapeutics Inc. (NASDAQ:AXSM) said Tuesday that solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor, led to a significant improvement on the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score compared with placebo in the Phase III FOCUS study, meeting its primary objective. At week six, a 150 mg dose of the therapy led to a mean reduction from baseline of 17.7 points vs. 14.3 for placebo (p=0.039)...